Study | Protocol-Patients | Local relapse | Survival |
---|---|---|---|
Fujimori 1997 (22) | P.E based CT × 2–4 → S | 5% | Overall MD: 61.9 months (21 pts) |
Patients: 22 | 3 year: 66.7% | ||
Resected pts: 21/22 | Stage | ||
I-II: 3 year → 73.3% | |||
IIIA: 3 year → 42.9% | |||
p = 0.018 | |||
Eberhardt 2003 (13) | Stage IB-IIA: P.E × 4 → S (8 pts) | 0% | Overall survival (46 pts) |
Stage IIB-IIIA: P.E × 3 → concurrent CTRx (Hf-RTx) → S (38) | 5 year: 39% | ||
10 year: 35% | |||
Resected pts: 30/46 (stage IB-IIA:8/IIB-IIIA:22) | Stage IIB-IIIA (22 pts) | ||
5 year: 44% | |||
10 year: 41% | |||
Rostad 2004 (15) | CT or concurrent CTRx: 2404 pts | Stage I – 5 year survival | |
Surgery: 38 pts | 11.3% (CT or CTRx) | ||
Surgery + additional treatment (CT, RTx, CTRx): 25/38 pts | 44.9% (surgery ± additional treatment) | ||
Brock 2005 (19) | S ± adjuvant or induction CT | Stage I | |
5 year: 58% | |||
82 pts | |||
Stages II, III and IV | |||
5 year: 18%, 23%, 0% | |||
p < 0.001 | |||
Tsuchiya 2005 (20) | S → P.E × 4 (62 pts) | 10% | Pathological Stage (5 year survival): |
Resected pts: 61/62 | I: 73% | ||
II: 38% | |||
IIIA: 39% | |||
Granetzny 2006 (14) | S → CTRx (64 pts) – stage I, II | MD | |
Primary S: 31,3 months | |||
CT → S → CT + RTx (thoracic, cranial) (31 pts) – stage IIIA, IIIB | S after CT: 31,7 months (N2-), 12.4 months (N2+) | ||
Bischof 2007 (21) | S → CT ± RTx ± PCI | MD: 47 months | |
39 pts: CT 35 pts, RTx 16 pts, PCI 21 pts | 1,3, 5 year survival: 97%, 58%, 49% | ||
Lim 2008 (20) | 59 pts: 43 pure SCLC, 16 pts:mixed histology | 5 year survival: 52% | |
Adjuvant therapy: 16/59 | T, N, UICC stage not statistically significant |